Smarter leaders trust GlobalData

Premium Insights Innovation in pharma: modified vector HIV-1 vaccines

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

GSK plc

Curevac NV

View all

However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilizing and reaching maturity.

Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.

80+ innovations will shape the pharmaceutical industry

According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 668,000 patents, there are 80+ innovation areas that will shape the future of the industry.

Within the emerging innovation stage, engineered multi-specific antibodies, tyrosine kinase inhibitors, and mutant DNA polymerases are disruptive technologies that are in the early stages of application and should be tracked closely. Phenotypic drug screening, antibody-drug conjugates, and polysaccharide-protein conjugate vaccines are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are drug delivery nanoparticles and antibody encoding polynucleotide libraries, which are now well established in the industry.

Innovation S-curve for the pharmaceutical industry

Modified vector HIV-1 vaccines is a key innovation area in the pharmaceutical industry

Modified vector HIV-1 vaccines are vaccines that use recombinant DNA technology to modify viruses or bacteria such as adenovirus or vaccinia virus to carry HIV genes. The rationale behind this approach is to stimulate an immune response that will produce antibodies that can block HIV infection.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 370+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of modified vector HIV-1 vaccines.

Key players in modified vector HIV-1 vaccines – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.   

‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.  

Patent volumes related to modified vector HIV-1 vaccines

GSK is one of the leading patent filers in modified vector HIV-1 vaccines. The company has filed several patents for HIV vaccine development and has developed multiple drugs for the same. It also acquired ViiV Healthcare, which is primarily involved vaccine development for the treatment of HIV.

In terms of application diversity, Xigen leads the pack, while Curevac and Globeimmune stood in second and third positions, respectively. By means of geographic reach, NoNO held the top position, followed by Curevac and Globeimmune.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.